The LBI-HTA in Austria published 7 HTA reports relevant for medical devices in 2017; none of the technologies was recommended for inclusion without limitations

The Ludwig Boltzmann Institute– Health Technology Assessment (LBI-HTA) is the main health technology appraisal body in Austria. It is an independent organization that on request provides scientific support for decision-making regarding the inclusion of health technologies (medical devices and in-vitro diagnostics) into the national benefit catalogue by the Ministry of Health. LBI-HTA produces different types of reports. The most relevant reports regarding market access of medical devices are so-called decision support documents (DSD) which are systematic, scientific review papers with a focus on efficacy and safety of technology (HTA reports).

In decision support documents, the LBI-HTA gives its evidence-based recommendation in the form of four categories:

1. Recommendation for inclusion
2. Limmited recommendation for inclusion
3. Preliminary no recommendation for inclusion
4. No recommendation for inclusion

Recommendations by the LBI-HTA are not binding, yet, they are in 90 % of cases followed by the decision maker, the Federal Health Commission (BGK).

During the year 2017, the LBI-HTA produced seven decision support documents with relevance for medical devices of which 2 were updates of previous reports. Following were the report titles and LBI-HTA’s recommendation expressed in category numbers described above:

• Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS; 3
• Prostate artery embolisation for benign prostatic hyperplasia; 3
• Radiofrequency ablation for metastatic spinal lesions; 2
• Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD); 3
• Leadless pacemakers for right ventricle pacing, update; 3
• Repetitive transcranial magnetic stimulation for treatment-resistant major depression; 2
• Percutaneous volume reduction of the disc with focus on chemonucleolysis, update
  • Recommendation for chemonucleolysis: 2
  • Recommendation for further percutaneous intervertebral disk volume reduction (percutaneous nucleotomy, percutaneous laser disc decompression or IDET): 3

All reports published in 2017 are available in the LBI-HTA repository.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.